Jennifer Ullman
Acute Care · New York, NYNPI 1508163072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Abbott at 47.1% of the total. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $40.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- AstraZeneca$745
- E.r. Squibb & Sons, L.L.C.$353
- Novartis$319
- Cvrx, Inc.$285
- Merck$260
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,562100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $3,089 |
| AstraZeneca | 27 | $745 |
| E.r. Squibb & Sons, L.L.C. | 15 | $353 |
| Novartis | 11 | $319 |
| Cvrx, Inc. | 6 | $285 |
| Merck | 11 | $260 |
| Boston Scientific | 3 | $256 |
| Boehringer Ingelheim | 9 | $254 |
| Lexicon Pharmaceuticals, Inc. | 7 | $159 |
| Atricure, Inc. | 1 | $141 |
| Abiomed | 1 | $112 |
| Lilly USA, LLC | 3 | $61 |
| Novo Nordisk | 3 | $57 |
| Pfizer | 3 | $55 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $52 |
| Impulse Dynamics (USA) Inc. | 1 | $49 |
| Kestra Medical Technology Services, Inc. | 1 | $47 |
| Amgen | 2 | $44 |
| Philips North America LLC | 1 | $42 |
| Bridgebio Pharma, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Heartflow, Inc. | 1 | $23 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,141
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$810
- CardioMEMS HF System$289
- Barostim Neo System$149
- SYNERGY ABLATION SYSTEM$141
- WAINUA$125
- LEQVIO$125
- FARXIGA$116
How this compares
$6,562 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $273,344 |
| EntrestoSacubitril/Valsartan | 112 | $105,971 |
| JardianceEmpagliflozin | 108 | $91,243 |
| EliquisApixaban | 74 | $62,464 |
| FarxigaDapagliflozin Propanediol | 49 | $35,810 |
| Metoprolol Succinate | 104 | $1,471 |
| Eplerenone | 20 | $1,366 |
| Atorvastatin Calcium | 72 | $930 |
| Torsemide | 45 | $586 |
| Rosuvastatin Calcium | 25 | $478 |
| Spironolactone | 80 | $463 |
| Digoxin | 28 | $431 |
| Carvedilol | 69 | $395 |
| ClopidogrelClopidogrel Bisulfate | 21 | $286 |
| Valsartan | 11 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $55 | $335,80886 claims |
| NovartisEntresto | $319 | $105,971112 claims |
| Boehringer IngelheimJardiance | $254 | $91,243108 claims |
| AstraZenecaFarxiga | $745 | $35,81049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in New York
- Daniel VerinaNew York$464K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Julie Anne RoldanNew York$10K
- Lauren Dela CruzNew York$9K
- Kristen DonchezNew York$8K
- Tracy Valerie BertizNew York$7K
- Sara-Jane DakroubNew York$6K
- Kathryn CiccoliniNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.